🇫🇷Europe

Medical Device Regulation in France

France is the second-largest medical device market in Europe and regulates devices under the EU Medical Device Regulation (EU MDR 2017/745). The National Agency for the Safety of Medicines and Health Products (ANSM) is the national competent authority. France has a particularly active vigilance system and plays a leading role in EU medical device policy through its involvement in MDCG and IMDRF.

FrameworkEU Medical Device Regulation (MDR) 2017/745; EU In Vitro Diagnostic Regulation (IVDR) 2017/746; French Public Health Code (Code de la santé publique), Articles L.5211-1 et seq.; Ordonnance No. 2022-582 adapting French law to EU MDR
Classification systemClass I / Class IIa / Class IIb / Class III
Primary agencyANSM
RegionEurope
References tracked5
Updates this year24

Sources Tracked by Qalico

Qalico continuously monitors 5 references across guidelines, regulations, and standards for France.

Regulations

Code de la Santé Publique1 ref

Guidelines

HAS — Latest Updates4 refs

Device Classification

Class IClass IIaClass IIbClass III

France follows the EU MDR classification system. Class I devices are low risk (e.g., non-sterile dressings, manual wheelchairs). Class IIa devices are low-moderate risk (e.g., contact lens care products, diagnostic electrodes). Class IIb devices are moderate-high risk (e.g., condoms, infusion pumps). Class III devices are high risk (e.g., hip prostheses, coronary stents). Classification follows Annex VIII of EU MDR.

Official classification guidance →

Standards & Key Principles

Applicable Standards

ISO 13485:2016 – Quality Management Systems for Medical DevicesISO 14971:2019 – Risk Management for Medical DevicesIEC 60601-1 – Medical Electrical Equipment SafetyEN ISO 10993 – Biological Evaluation of Medical DevicesEN 62304 – Medical Device Software Lifecycle ProcessesNF EN ISO 13485 – French Adoption of ISO 13485NF EN ISO 14971 – French Adoption of ISO 14971

Key Principles

  • Medical devices must bear the CE mark under EU MDR 2017/745 to be placed on the French market.
  • France has a robust matériovigilance system requiring mandatory reporting of incidents by manufacturers, healthcare professionals, and users.
  • Notified body involvement is required for Class IIa, IIb, and III devices. France hosts the notified body GMED (LNE/G-MED).
  • Non-EU manufacturers must designate an EU-based authorized representative.
  • Reimbursement requires a separate evaluation by HAS/CNEDiMTS, which is independent from CE marking.
  • Clinical investigations in France require ANSM authorization and ethics committee (CPP) approval.

Pre-Market Requirements

CE Marking and Conformity Assessment

Devices must comply with EU MDR 2017/745 and bear CE marking. France hosts the notified body GMED (LNE/G-MED, NB 0459). Notified body assessment is required for Class IIa, IIb, and III devices.

Technical Documentation

Comprehensive technical documentation per EU MDR Annexes II and III is required, covering all aspects of device design, manufacturing, risk management, and clinical evidence.

Clinical Evaluation

Clinical evaluations per EU MDR Article 61 are mandatory. Clinical investigations in France require ANSM authorization and a favorable opinion from a Comité de Protection des Personnes (CPP).

EUDAMED and National Registration

Registration in EUDAMED is required. Manufacturers may also need to fulfill French national notification requirements with ANSM.

Reimbursement (HAS Evaluation)

For devices seeking reimbursement in France, a separate application to HAS/CNEDiMTS is required. This evaluates the clinical benefit and added clinical benefit of the device.

Post-Market Requirements

Matériovigilance

France operates a comprehensive matériovigilance system. Manufacturers, healthcare professionals, and patients must report serious incidents to ANSM. This is coordinated with the EU-wide vigilance system under EU MDR.

Post-Market Surveillance

PMS systems must be maintained per EU MDR. PSURs are required for Class IIa, IIb, and III devices. France may request additional national PMS data.

Post-Market Clinical Follow-Up

PMCF studies are required to continuously validate clinical safety and performance. France places particular emphasis on PMCF for high-risk implantable devices.

Market Surveillance and Inspections

ANSM conducts regular inspections of manufacturers, authorized representatives, and distributors operating in France to verify compliance with EU MDR and national requirements.

International Recognition & Reliance

European Union

CE-marked devices under EU MDR are freely circulated across all EU/EEA member states.

Switzerland

CE-marked devices from EU member states are recognized in Switzerland under the MRA framework with certain conditions.

Stay on top of regulatory changes in France

Qalico monitors publications from ANSM in real time, surfacing updates that matter to your device category — so your team never misses a critical change.